Want to see HK:6681 full AI Analyst Report?
6681 Stock Chart & Stats
HK$5.70
--
Market closed
HK$5.70
--
Day’s Range― - ―
52-Week RangeHK$1.41 - HK$17.79
Previous CloseN/A
VolumeN/A
Average Volume (3M)20.05M
Market Cap
HK$2.04B
Enterprise ValueHK$1.81K
Total Cash (Recent Filing)HK$430.36M
Total Debt (Recent Filing)HK$565.52M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Mar 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding1,358,278,000
10 Day Avg. Volume12,069,110
30 Day Avg. Volume20,049,348
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)69.27
Price to Sales (P/S)30.65
P/FCF Ratio-32.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)HK$471.47M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthRapid top-line expansion indicates increasing product adoption and market penetration. Sustaining this growth could improve operating leverage over time, although the company must convert revenue gains into healthier margins and cash generation.
Healthy Gross MarginA 41% gross margin suggests the products retain meaningful economic value after direct costs. This provides a foundation for eventual profitability if management can scale revenue while controlling operating expenses and research investment.
Equity Position ImprovedThe return to positive equity represents a meaningful balance-sheet improvement from prior deficits. It may provide a stronger capital base for continued operations, although the benefit remains limited while leverage and losses stay elevated.
Bears Say
Deep And Ongoing LossesSevere operating losses show that current revenue is insufficient to cover the cost structure. Until expenses scale more efficiently and the company reaches breakeven, growth may continue to require external funding and carry substantial execution risk.
High And Rising LeverageIncreasing debt and a highly leveraged capital structure reduce financial flexibility and raise refinancing exposure. Heavy obligations can constrain investment in growth and amplify the consequences of continued losses or slower revenue expansion.
Persistent Cash BurnNegative operating and free cash flow indicate the business is not yet self-funding despite strong revenue growth. Continued cash burn increases dependence on financing, which is more challenging and potentially dilutive or costly given the elevated debt load.
BrainAurora Medical Technology Limited News
6681 FAQ
What was BrainAurora Medical Technology Limited’s price range in the past 12 months?
BrainAurora Medical Technology Limited lowest stock price was HK$1.41 and its highest was HK$17.79 in the past 12 months.
What is BrainAurora Medical Technology Limited’s market cap?
BrainAurora Medical Technology Limited’s market cap is HK$2.04B.
When is BrainAurora Medical Technology Limited’s upcoming earnings report date?
BrainAurora Medical Technology Limited’s upcoming earnings report date is Mar 26, 2027 which is in 208 days.
How were BrainAurora Medical Technology Limited’s earnings last quarter?
BrainAurora Medical Technology Limited released its earnings results on Aug 28, 2026. The company reported -HK$0.117 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is BrainAurora Medical Technology Limited overvalued?
According to Wall Street analysts BrainAurora Medical Technology Limited’s price is currently Overvalued.
Does BrainAurora Medical Technology Limited pay dividends?
BrainAurora Medical Technology Limited does not currently pay dividends.
What is BrainAurora Medical Technology Limited’s EPS estimate?
BrainAurora Medical Technology Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BrainAurora Medical Technology Limited have?
BrainAurora Medical Technology Limited has 1,358,278,000 shares outstanding.
What happened to BrainAurora Medical Technology Limited’s price movement after its last earnings report?
BrainAurora Medical Technology Limited reported an EPS of -HK$0.117 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.954%.
Which hedge fund is a major shareholder of BrainAurora Medical Technology Limited?
Currently, no hedge funds are holding shares in HK:6681
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BrainAurora Medical Technology Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
Company Description
BrainAurora Medical Technology Limited
BrainAurora Medical Technology Limited provides system integral software solutions for hospitals and research projects in Mainland China. The company develops medical-grade digital therapy (DTx) products for cognitive impairment. It offers the evaluation and intervention of cognitive impairments to treat vascular diseases, neurodegenerative diseases, psychological disorders, and child development deficiencies. The company develops the Brain Function Information Management Platform software system, an evidence-based, medical-grade DTx product; Basic Cognitive Testing Software, an assessment of patients for basic cognitive capacity; Cognitive Ability Supplemental screening and assessment software, a solution designed to facilitate healthcare professionals assessment of patients; and Dyslexia Supplemental Screening and Assessment Software, a solution designed to facilitate the assessment of risk of developmental dyslexia in children. It also develops covid-19 induced cognitive impairment assessment and recovery training software; ADHD assessment and treatment software; quantitative cognitive assessment software for depression; depression treatment software; and cognitive impairment assessment software and cognitive impairment treatment software solutions. In addition, the company provides marketing services. BrainAurora Medical Technology Limited was founded in 2012 and is headquartered in Shaoxing, China.
Technical Analysis
Hangzhou Tigermed Consulting Co., Ltd. Class H
―
Ocumension Therapeutics
―
Frontage Holdings Corp.
―
Lepu Biopharma Co. Ltd. Class H
―
Zhaoke Ophthalmology Ltd.
―